COSA 2019, 12 - 14 November 2019 Adelaide Convention Centre, South Australia

Breakfast Sessions

Tuesday 12 November 2019

What is needed to ensure optimal care and outcomes for older people with cancer in Australia 

Date: Tuesday 12 November 2019 
Time: 7:00am - 8:15am 
Description: There is international momentum for focused efforts to improve care and outcomes for older people with cancer, including international Guidelines. This breakfast session aims to promote discussion from consumer, clinician, service and policy lens about what needs to change to improve outcomes for older people with Cancer in the Australian setting 

Speaker: TBC

Chairperson: TBC 

This breakfast session is sponsored by

COSA Logo BLUE RGB 72dpi1

Genetic Testing is not Just for Girls! Somatic (Tumour) and Germline Testing in Prostate Cancer: Guiding Therapy and Saving Lives.

Date: Tuesday 12 November 2019 
Time: 7:00am - 8:15am 
Description: Genetic testing in women with ovarian cancer or triple negative breast cancer is accepted, available and usually Medicare funded. Why is it not more common in men? We know men with metastatic prostate cancer, unselected by age or family history, have >10% chance of carrying a germline mutation in a homologous repair (HR) gene, with BRCA2 making up 66%. This has important implications for patients. Prostate cancers containing BRCA2 mutations have been shown to be uniquely aggressive. The PSA velocity in these men is unreliable making aggressive treatment rather than active surveillance the initial treatment of choice. Men with BRCA2 mutations and metastatic disease demonstrate high response rates to PARP inhibitors and platinum-based chemotherapy. And, for men with mutations in mismatch repair genes, such as in Lynch syndrome, the tumours are highly immunogenic. So, when should you consider genetic testing, what test to choose and what will the test tell you? international guidelines such as NCCN’s state “germline genetic testing [BRCA1, BRCA2, ATM and PALB2] should be considered in all men with high risk or metastatic prostate cancer” as well as screening for Lynch syndrome [MLH1, MSH2, MSH6, PMS2] “at diagnosis of castration resistant prostate cancer”. How does that translate into the Australian setting? This practical session will explain how to interpret somatic (tumour based) testing, whether ordered in the clinic or via a research trial. You will learn when germline (hereditary) testing should be performed and the implications for patients and their blood relatives. Using case studies, we will demonstrate how genetic testing is affordable and accessible and guides treatment decisions in men with prostate cancer, at all stages of their disease.

Speaker: Dr Hilda High, Genetic Oncologist Head of Sydney Cancer Genetics

Chairperson: Dr Gerald Goh, Senior Regional Segment Marketing Manager, Oncology Illumina Asia Pacific Japan

This breakfast session is sponsored by

ILLUMINA LOGO CMYK new

 

 
Wednesday 13 November 2019

Identifying and addressing common sex and gender-based conflicts among patients, partners and health care professionals: We can do this!

Date: Wednesday 13 November 2019 
Time: 7:00am - 8:45am 
Description: So much public attention has been given to sex and gender differences that it may seem easier (and safer)  to  simply avoid such emotionally charged  conversations . This is especially true in health care settings which are, by nature, highly intimate,  team based  and yet  conflict-avoidant.  But within courageous sex and gender based  conversations lies the potential for greater inter/intrapersonal  understanding, personal growth and healthier health care systems.  Diversity, conflict, creativity, personal accountability and compassion comprise essential elements  to creating healthier heath care systems and by extension societies. Healthcare professionals are deeply grounded in humanistic values and tend to have higher levels of education so we should be able to initiate conversations  relating to sex, gender, generational differences and the use of power.   If we do not have these deeply honest conversations, who will?  This highly interactive session will be 10% didactic (to set up the structure)  and 90%  topic-driven by the participant responses to problem scenarios.  But be warned, this strengths-based opportunity will focus on what we can actually do today,  to move forward together,  as role-models by acting in ways that we will be most proud of now and  in the near and distant  future.  Let’s alchemize experiences and emotions into meaningful and effective behaviors together. We can do this!

Speaker: Matt Loscalzo  

Chairperson: TBC 

This breakfast session is sponsored by

COSA Logo BLUE RGB 72dpi1

Leadership in cancer care: a multi-professional approach 

Date: Wednesday 13 November 2019 
Time: 7:00am - 8:45am 
Description: Good leadership is key for high quality cancer care but not always easy to achieve. During this session Lena will discuss strategies on how to ensure effective team work through good leadership, effective team communication and the importance of clinical role models. The concept of psychological safety will also be discussed and also the connection between patient and occupational safety. 

Speaker: Lena Sharp 

Chairperson: Mei Krishnasamy 

This breakfast session is sponsored by

COSA Logo BLUE RGB 72dpi1

 
Thursday 14 November 2019

CALLED OUT: Exploring inequities and improvements for CALD patient access to cancer clinical trials 

Date: Thursday 14 November 2019 
Time: 7:00am - 8:45am 
Description: People from Culturally and Linguistically Diverse (“CALD”) communities are underrepresented in clinical trials due to various interrelated barriers to participation. These barriers include, but are not limited to, challenges with communication, opportunity and culture. For patients with low English proficiency, access to translation and interpreter services (“TIS”) throughout the clinical trial would reduce communication barriers to participation. Addressing these barriers is essential to improving disparities in patient outcomes and increasing the generalisability and impact of clinical trial results. In this session, we will explore various strategies for providing equitable access to clinical trials for CALD patients and hear from several key stakeholders in the sector. 

Speakers:

  • Christie Allan (Clinical Trials Lead – Cancer Council Victoria)

  • Tarishi Desai (Legal Policy Advisor, McCabe Centre for Law and Cancer)

  • Dr. Ben Smith (CONCERT Co-Deputy Director (Policy & Practice), Ingham Institute for Applied Medical Research)

  • Prof. Nikolajs Zeps (Director of Research and Development, Epworth Hospital)

  • Prof. Sanchia Aranda (CEO, Cancer Council Australia)

  • A/Prof. Tam Nguyen (Deputy Director of Research, St Vincent’s Hospital Melbourne) and

  • Community representative (TBC).

Chairperson: Hayley Jones (Acting Director, McCabe Centre for Law and Cancer), 

This breakfast session is sponsored by

cancer council

Best of the Best Poster Session A 

Date: Thursday 14 November 2019 
Time: 7:15am - 9:00am 

Best of the Best Poster Session B - Clinical Research

Date: Thursday 14 November 2019 
Time: 7:15am - 9:00am 

 


Our Sponsors